search
Back to results

Efficacy and Safety of S (+) - Ibuprofen in Osteoarthritis Pain (APS003/2020)

Primary Purpose

Osteoarthritis

Status
Completed
Phase
Phase 2
Locations
Brazil
Study Type
Interventional
Intervention
S (+) - Ibuprofen
Ibuvix® - ibuprofen
Sponsored by
Apsen Farmaceutica S.A.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Osteoarthritis focused on measuring Nonsteroidal anti-inflammatory, Pain, Ibuprofen, Inflammation, Anti-inflammatory, Pain control, Osteoarthritis, Pain relief, Enzyme Inhibitors

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Main Inclusion Criteria:

  • Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the informed consent forms;
  • Patients aged from 18 to 75 with a diagnosis of knee and/or hip osteoarthritis according to American College of Rheumatology (ACR) criteria.

Main Exclusion Criteria:

  • Known hypersensitivity to the formula components used during the clinical trial;
  • Previous history of alcohol or drugs abuse diagnosed by DSM-V;
  • Current or previous history (less than 12 months) of smoking;
  • Have clinically relevant abnormal laboratory results according to medical evaluation;
  • Women who are pregnant, lactating, or positive for β - hCG urine test;

Sites / Locations

  • Apsen Farmacêutica S.A.

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

S (+) - Ibuprofen

Ibuvix® - ibuprofen

Arm Description

S (+) - Ibuprofen (1 coated tablet) + placebo of Ibuvix® - ibuprofen (1 coated tablet) Every 6 hours for 28 days.

Ibuvix® - ibuprofen (1 coated tablet) + placebo of S (+) - Ibuprofen (1 coated tablet) Every 6 hours for 28 days.

Outcomes

Primary Outcome Measures

Mean reduction of pain measured by the WOMAC Osteoarthritis Index (pain)

Secondary Outcome Measures

Patient Global Impression of Improvement-I (PGI-I)
Proportion of participants among the groups to discontinue the trial due to treatment non-tolerability

Full Information

First Posted
November 18, 2020
Last Updated
July 13, 2023
Sponsor
Apsen Farmaceutica S.A.
search

1. Study Identification

Unique Protocol Identification Number
NCT04637529
Brief Title
Efficacy and Safety of S (+) - Ibuprofen in Osteoarthritis Pain
Acronym
APS003/2020
Official Title
National, Multicentre, Randomized, Double-blind, Double-dummy Phase II Clinical Trial to Evaluate the Efficacy and Safety of S (+) - Ibuprofen for Pain Control in Individuals With Osteoarthritis
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
August 5, 2022 (Actual)
Primary Completion Date
June 30, 2023 (Actual)
Study Completion Date
June 30, 2023 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Apsen Farmaceutica S.A.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this study is to evaluate the efficacy of S (+) - ibuprofen compared to an active treatment for pain control in individuals diagnosed with osteoarthritis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis
Keywords
Nonsteroidal anti-inflammatory, Pain, Ibuprofen, Inflammation, Anti-inflammatory, Pain control, Osteoarthritis, Pain relief, Enzyme Inhibitors

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
176 (Actual)

8. Arms, Groups, and Interventions

Arm Title
S (+) - Ibuprofen
Arm Type
Experimental
Arm Description
S (+) - Ibuprofen (1 coated tablet) + placebo of Ibuvix® - ibuprofen (1 coated tablet) Every 6 hours for 28 days.
Arm Title
Ibuvix® - ibuprofen
Arm Type
Active Comparator
Arm Description
Ibuvix® - ibuprofen (1 coated tablet) + placebo of S (+) - Ibuprofen (1 coated tablet) Every 6 hours for 28 days.
Intervention Type
Drug
Intervention Name(s)
S (+) - Ibuprofen
Intervention Description
S (+) - Ibuprofen + placebo of Ibuvix®
Intervention Type
Drug
Intervention Name(s)
Ibuvix® - ibuprofen
Intervention Description
Ibuvix® + placebo of S(+) - Ibuprofen
Primary Outcome Measure Information:
Title
Mean reduction of pain measured by the WOMAC Osteoarthritis Index (pain)
Time Frame
Baseline (day 0) and Week 4 (day 28)
Secondary Outcome Measure Information:
Title
Patient Global Impression of Improvement-I (PGI-I)
Time Frame
Week 4 (day 28)
Title
Proportion of participants among the groups to discontinue the trial due to treatment non-tolerability
Time Frame
From Baseline (day 0) to Week 4 (day 28)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Main Inclusion Criteria: Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the informed consent forms; Patients aged from 18 to 75 with a diagnosis of knee and/or hip osteoarthritis according to American College of Rheumatology (ACR) criteria. Main Exclusion Criteria: Known hypersensitivity to the formula components used during the clinical trial; Previous history of alcohol or drugs abuse diagnosed by DSM-V; Current or previous history (less than 12 months) of smoking; Have clinically relevant abnormal laboratory results according to medical evaluation; Women who are pregnant, lactating, or positive for β - hCG urine test;
Facility Information:
Facility Name
Apsen Farmacêutica S.A.
City
São Paulo
ZIP/Postal Code
04753-001
Country
Brazil

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Efficacy and Safety of S (+) - Ibuprofen in Osteoarthritis Pain

We'll reach out to this number within 24 hrs